AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...
GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...
- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...
Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to ac...
Oxford Medical Products is pleased to announce positive topline results from the first randomised controlled trial (RCT) of Sirona, its innova...
Innovative Trials is the second fastest-growing, woman-powered UK company in the clinical research sector and in the top 200 overall, according to ...
Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...
Symbiosis acquires a 20,000 sq/ft building in Stirling, UK, to house new high-tech medicines manufacturing capacity, financed by £1...
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with ne...
RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, has today announced completion of the phase 2 expans...
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapi...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at U...
© 2025 Biopharma Boardroom. All Rights Reserved.
